Halozyme Therapeutics Elects New Board Member

Details

announced the election of James Lang to its Board of Directors. Mr. Lang's term will end at the Company's annual meeting of stockholders in 2027. He will receive compensation under the Company's non-employee director compensation program, which includes cash retainers for Board and committee service, restricted stock, and stock option awards. There are no arrangements or understandings for his election, nor are there related person transactions between Mr. Lang and the Company.

Items reported

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.